Scholarlink

Background <p>The 2018 World Cancer Research Fund (WCRF)/American Institute for Cancer Research (AICR) Cancer Prevention Recommendations aim to lower cancer incidence. Our study explored associations between adherence to these Recommendations and the risk of first cancer incidence in a US cohort.</p> Methods <p>Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial Study participants who were cancer-free at baseline and who had height, weight, physical activity, diet, and alcohol data to estimate the standardized 2018 WCRF/AICR Score (<i>n</i> = 69,061) were included. Associations between Score and cancer endpoints, including any cancers, any of the 17 WCRF/AICR-reviewed cancers, and individual cancer sites were investigated using multivariable Cox proportional hazard models, adjusting for covariates.</p> Results <p>Mean Score was 3.55 points (range 0–7). During a median follow-up of 10 years, 11,109 participants developed cancer. The 2018 WCRF/AICR Score was significantly inversely associated with risk of any cancers (HR per 1-point increment:0.97; 95% CI: 0.95–0.99), any of the 17 WCRF/AICR-reviewed cancers (HR: 0.97; 95% CI: 0.95–0.99), pancreatic (HR:0.86; 95% CI: 0.78–0.96), and breast (HR:0.91; 95% CI: 0.87–0.96) cancers.</p> Discussion <p>Our findings support adherence to the WCRF/AICR Cancer Prevention Recommendations for reducing risk of cancer incidence, particularly breast and pancreatic cancers, in the US.</p> Clinical registration numbers <p>The PLCO Cancer Screening Trial is registered with ClinicalTrials.gov: NCT00002540 (Prostate), NCT01696968 (Lung), NCT01696981 (Colorectal), NCT01696994 (Ovarian), and NCT00339495 (EEMS).</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Adherence to the 2018 World Cancer Research Fund/American Institute for Cancer Research Cancer Prevention Recommendations and risk of lifestyle-related cancers in the prostate, lung, colorectal, and ovarian cancer screening trial

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年11月19日

查看全文
  • Fiona C. Malcomson,
  • Marissa M. Shams-White,
  • Jill Reedy,
  • Wen-Yi Huang,
  • Steven C. Moore,
  • Erikka Loftfield

摘要

Background

The 2018 World Cancer Research Fund (WCRF)/American Institute for Cancer Research (AICR) Cancer Prevention Recommendations aim to lower cancer incidence. Our study explored associations between adherence to these Recommendations and the risk of first cancer incidence in a US cohort.

Methods

Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial Study participants who were cancer-free at baseline and who had height, weight, physical activity, diet, and alcohol data to estimate the standardized 2018 WCRF/AICR Score (n = 69,061) were included. Associations between Score and cancer endpoints, including any cancers, any of the 17 WCRF/AICR-reviewed cancers, and individual cancer sites were investigated using multivariable Cox proportional hazard models, adjusting for covariates.

Results

Mean Score was 3.55 points (range 0–7). During a median follow-up of 10 years, 11,109 participants developed cancer. The 2018 WCRF/AICR Score was significantly inversely associated with risk of any cancers (HR per 1-point increment:0.97; 95% CI: 0.95–0.99), any of the 17 WCRF/AICR-reviewed cancers (HR: 0.97; 95% CI: 0.95–0.99), pancreatic (HR:0.86; 95% CI: 0.78–0.96), and breast (HR:0.91; 95% CI: 0.87–0.96) cancers.

Discussion

Our findings support adherence to the WCRF/AICR Cancer Prevention Recommendations for reducing risk of cancer incidence, particularly breast and pancreatic cancers, in the US.

Clinical registration numbers

The PLCO Cancer Screening Trial is registered with ClinicalTrials.gov: NCT00002540 (Prostate), NCT01696968 (Lung), NCT01696981 (Colorectal), NCT01696994 (Ovarian), and NCT00339495 (EEMS).